The findings
Cinnamon lowers fasting glucose about 10 to 25 mg/dL in type 2 diabetes across the pooled trials, and has never been shown to move HbA1c. Nearly every trial used cassia, the form whose coumarin content reaches the European daily intake ceiling at two to three grams; the Ceylon form sold as safer barely appears in the trials at all.
Cinnamon lowers fasting blood sugar a little in people with type 2 diabetes, about 10 to 25 milligrams per deciliter across the pooled trials, and it has never been shown to move HbA1c, the number diabetes care actually runs on. But the fact a buyer needs first is not the effect size; it is the species name. Nearly every trial behind the glucose claim used cassia cinnamon, and cassia is the form that carries a liver-related ceiling at supplement doses. The form sold as the safe choice, Ceylon cinnamon, barely appears in the trials at all. The evidence and the safety sit on opposite forms, and any honest account of cinnamon has to hold both at once. Longevity Lab Report grades cinnamon C+ on evidence and C+ on worth it, at $8 to $12 a month.
What the trials show
The field starts small. A 2003 study in Diabetes Care gave 60 people with type 2 diabetes 1, 3, or 6 grams of cassia cinnamon a day and reported fasting glucose down 18 to 29 percent. That study, small and short, is the origin of nearly every cinnamon claim in circulation, and its percentages are the dialect the claims still speak. In September 2025, Diabetes Care issued a formal Expression of Concern about this trial, after an independent statistical review found baseline differences between its groups that were inconsistent with proper randomization, unclear reporting of how patients were randomized and blinded, and no dropouts in any group; the journal could not reach the authors or obtain the underlying data. The trial's large reductions have never been reproduced at that size, and its numbers stand as unverified. The pooled record since is more modest and more believable. A 2013 meta-analysis by Allen and colleagues in the Annals of Family Medicine, covering 10 trials and 543 patients, found fasting glucose down about 25 mg/dL on doses from 120 mg to 6 grams a day over 4 to 18 weeks, with high heterogeneity across the trials it pooled. Later reviews land in the same band, roughly 10 to 25 mg/dL, in diabetes or prediabetes.
What the record does not show matters as much. HbA1c, the three-month average that treatment decisions actually turn on, has no robust effect: the changes reported are small, inconsistent, and often null. In people without diabetes, the glucose effect is negligible. And the trials are short, weeks to a few months, at doses a spice rack would call large: 1 to 6 grams a day is a teaspoon to two teaspoons of powder, every day, not a dusting on coffee.
The two cinnamons
Cassia is the common cinnamon of North American grocery shelves and nearly all supplements, and it is what the trials used. It is also rich in coumarin, a compound the liver handles poorly at sustained high intakes. Surveys of the spice find cassia coumarin at 0.7 to 12.2 milligrams per gram, averaging 3 to 5. The European Food Safety Authority's tolerable daily intake for coumarin is 0.1 mg per kilogram of body weight, about 7 mg a day for a 70-kilogram adult. Two to three grams of average cassia, under a teaspoon, reaches that ceiling. The trial doses that produced the glucose effect, 1 to 6 grams of cassia a day, sit at and above it.
Ceylon cinnamon, sold as true cinnamon, carries coumarin in trace amounts in the same surveys, 0.004 to 0.04 mg per gram, which removes the ceiling problem at any plausible dose. What it does not carry is the evidence: the trials are cassia trials, and Ceylon's own glucose record is thin to the point of absence. A buyer who switches to Ceylon for safety has left the studied substance behind. That is the inversion at the center of this topic, and it is why the grade is a C+ and not higher in either direction: the effect is real on the form with the limit, and unproven on the form without one.
What the guidelines say
No guideline body recommends cinnamon for diabetes or prediabetes, and the alignment is complete enough to print as a list. The National Center for Complementary and Integrative Health states that research does not clearly support cinnamon for any health condition. The American Diabetes Association's position, carried in its standards coverage, is that the evidence does not support cinnamon supplementation for glucose control. In the United Kingdom, neither NICE nor the NHS recommends it for diabetes or prediabetes. Four bodies, two continents, one answer, and it is the answer the pooled HbA1c record predicts.
Our grade and rationale
Longevity Lab Report grades cinnamon C+ on evidence and C+ on worth it, at $8 to $12 a month.
The C+ credits what is real: a consistent, modest fasting-glucose effect in type 2 diabetes across multiple poolings, on a substance people tolerate well at culinary doses. It stops there because the endpoint that matters, HbA1c, is unproven; because the effect's evidence belongs to cassia while its safety belongs to Ceylon; and because the doses trialed press against a regulatory intake ceiling for coumarin. The worth-it C+ follows the same shape: cinnamon is cheap, and at food-level amounts it is a pleasant way to make the meals that do matter more enjoyable, but as a blood-sugar intervention bought in capsules it promises in percentages what it delivers in single milligrams per deciliter, on the wrong form.
Safety
The interaction that matters is with diabetes medication: cinnamon's glucose effect, small as it is, can add to insulin and sulfonylureas and push blood sugar low, which is why the UK clinical guidance names the combination plainly. Cassia at supplement doses carries the coumarin question above; liver disease raises the stakes on it. Ceylon at culinary doses has no comparable file. Cinnamon is not a substitute for medication, and a person adjusting prescribed treatment around a spice has the relationship exactly backwards. This page is information, not medical advice.
What the experts say
Our expert library carries no tracked position on cinnamon. The loudest current claim in circulation, a short-form video recommending Ceylon cinnamon at a stated dose, could not be verified from the video itself, and an unverified dose does not enter our record or this page. The absence is worth printing in a market where the loudest voice on a spice is usually the one selling it: the tracked experts whose protocols fill this library do not build on cinnamon, and the one claim we chased down could not be sourced. What the page rests on instead is the trial record and the guideline list above.
Frequently asked questions
Does cinnamon lower blood sugar? In type 2 diabetes, fasting glucose falls about 10 to 25 mg/dL across the pooled trials, on doses from 120 mg to 6 grams a day. In people without diabetes, the effect is negligible.
Does it lower HbA1c? Not on any robust showing. The reported changes are small and inconsistent, and no guideline body treats cinnamon as a diabetes intervention.
Cassia or Ceylon? The trials used cassia; the safety margin belongs to Ceylon. Cassia at a gram or two a day stays near the coumarin ceiling for an average adult; Ceylon removes that concern and the evidence with it. Culinary amounts of either are a food question, not a supplement one.
How much is too much cassia? At average coumarin content, 2 to 3 grams a day reaches the European tolerable daily intake of about 7 mg for a 70-kilogram adult. Content varies widely by source, which is itself part of the problem.
Limitations: what we do not know
We do not know whether Ceylon cinnamon lowers glucose at all; it has barely been trialed. We do not know the long-term effect of daily cassia at trial doses, because the trials are short. We do not know the coumarin content of any given product on a shelf, because supplements are not standardized to it. And we do not know whether the fasting-glucose effect, sustained, changes any outcome a person would feel. What would change the grade: a properly sized Ceylon trial with HbA1c endpoints, or a long cassia trial that reads liver outcomes alongside glucose.
The record
The grades, the coumarin arithmetic, and the cost basis on this page are carried in full on the cinnamon record, which is updated as new trials land.
Supplements mentioned
Biomarkers mentioned
Grades are research summaries, not medical advice. Decisions about your own health belong with your clinician.